Skip to main content
. 2019 Nov 25;3(22):3688–3699. doi: 10.1182/bloodadvances.2019000576

Table 2.

Treatment results of all CoALL 07-03 patients according to presenting features

Factor n
pEFS Survival
Year 5 Year 10 Year 5 Year 10
Prob. SE Prob. SE P Prob. SE Prob. SE P
Immunophenotype
 Non-T NCI standard 474 87.9 1.5 87.1 1.6 .000 95.8 0.9 94.9 1.0 .000
 Non-T NCI high 189 77.2 3.1 75.9 3.1 86.2 2.5 83.7 2.8
 T-ALL NCI standard 32 78.1 7.3 78.1 7.3 .650 87.4 5.9 83.6 6.8 .990
 T-ALL NCI high 78 81.9 4.4 81.9 4.4 85.8 4.0 84.4 4.1
 Non-T 663 84.8 1.4 83.9 1.4 .260 93.0 1.0 91.7 1.1 .007
 T-ALL 110 80.8 3.8 80.8 3.8 86.2 3.3 84.1 3.5
Sex
 Male 429 82.4 1.8 81.7 1.9 .100 91.6 1.3 89.7 1.5 .290
 Female 344 86.6 1.8 85.7 1.9 92.7 1.4 91.9 1.5
Age at diagnosis
 Age <10 y 601 85.6 1.4 85.0 1.5 .021 93.8 1.0 92.7 1.1 .000
 Age ≥10 y 172 79.5 3.1 78.0 3.2 85.9 2.7 83.2 3.1
WBC, × 109/L
 WBC <25 525 86.0 1.5 84.3 1.6 .080 94.6 1.0 92.9 1.1 .002
 WBC ≥25 248 80.6 2.5 80.0 2.6 86.7 2.2 86.2 2.2
CNS status
 CNS negative 743 85.1 1.3 84.3 1.4 .001 93.1 0.9 91.8 1.0 .000
 CNS positive 20 60.0 11.0 60.0 11.0 64.6 10.8 59.2 11.1
t(12;21)
 ETV6-RUNX1 negative 517 80.0 1.8 78.8 1.8 .000 89.7 1.3 87.8 1.5 .000
 Positive 170 92.4 2.0 92.4 2.0 98.2 1.0 97.6 1.2

NCI, National Cancer Institute; Prob., probability.